IRVINE, Calif., Nov. 12, 2007 (PRIME NEWSWIRE) -- "For any drug or drug delivery company, approval of its products for use in humans is an enormous corporate development. But it's even more significant when said achievement occurs in the world's second most populous country," stated SmallCap Sentinel analyst D.R. Clark. "This morning, MIV Therapeutics Inc. (OTCBB:MIVT) a leading developer of next-generation coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced that the Drugs Controller General of India (DCGI), the governmental agency with regulatory authority over medical products, has approved two of the MIV's bare metal stents for manufacture and sale in India."
A comprehensive report focusing on MIV Therapeutics Inc. and developments in cardiovascular stents and drug delivery has been published by financial courier StockUpTicks.com and is available free of charge to the general public. The report will feature detailed information regarding MIVT and address related information and stent companies including Johnson & Johnson (NYSE:JNJ), Medtronic Inc. (NYSE:MDT), and Boston Scientific (NYSE:BSX).
To view the report in its entirety, please visit: http://stockupticks.com/profiles/10-16-07.html
"This achievement positions MIV in one of the largest stent markets in the world and gives the company manufacturing capability as they advance the clinical development of unique drug-eluting stents using advanced biocompatible coatings and drug delivery technology," Clark noted. "This passage in India is a watershed event for MIV Therapeutics even if it comes through the minute portal of a small stent placed in the heart of an Indian cardiac patient."
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices.
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $24,000 by MIV Therapeutics for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664